Intratumoral heterogeneity, treatment response, and survival outcome of ER-positive HER2-positive breast cancer.

In ER+HER2+ breast cancer, the presence of ER-HER2+ cells without HER2- cells was independently associated with pCR. Combined posttreatment Ki67 and pCR can be more precise in predicting prognosis than pCR alone.